scholarly journals TCT-220 Is Inhibition of Platelet Aggregation by Endogenous Endothelial Platelet Antagonists Enhanced by Oral Ticagrelor Mediated P2Y12 Blockade in Patients With Coronary Artery Disease?

2016 ◽  
Vol 68 (18) ◽  
pp. B89-B90
Author(s):  
Jennifer Rossington ◽  
Angela Hoye ◽  
Benjamin Spurgeon ◽  
Konstantinos Aznaouridis ◽  
Michael Cunnington ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Inhibition Of Platelet Aggregation ◽  
Artery Disease

Thrombopoietin and platelet aggregation in patients with stable coronary artery disease

Platelets ◽  
2017 ◽  
Vol 28 (8) ◽  
pp. 822-824
Author(s):  
Sanne Bøjet Larsen ◽  
Erik Lerkevang Grove ◽  
Søs Neergaard-Petersen ◽  
Morten Würtz ◽  
Anne-Mette Hvas ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Stable Coronary Artery Disease ◽  
Artery Disease

Accelerated coronary artery disease after heart transplantation: the role of enhanced platelet aggregation and thrombosis

1993 ◽  
Vol 233 (4) ◽  
pp. 343-350 ◽  
Author(s):  
M. LORGERIL ◽  
R. LOIRE ◽  
J. GUIDOLLET ◽  
P. BOISSONNAT ◽  
G. DUREAU ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Heart Transplantation ◽  
Artery Disease

scholarly journals Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease

TH Open ◽  
2021 ◽  
Vol 05 (03) ◽  
pp. e230-e238
Author(s):  
Oliver Buchhave Pedersen ◽  
Anne-Mette Hvas ◽  
Hans Beier Ommen ◽  
Steen Dalby Kristensen ◽  
Erik Lerkevang Grove
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Essential Thrombocythemia ◽  
Antiplatelet Effect ◽  
Immature Platelet Fraction ◽  
Increased Risk ◽  
Platelet Disorder ◽  
Patient Groups ◽  
Artery Disease

Abstract Background Patients with essential thrombocythemia (ET) and coronary artery disease (CAD) have increased risk of thromboembolic complications. In addition, a reduced antiplatelet effect of aspirin has been demonstrated in both patient groups. As ET is a platelet disorder, platelets may be more important for the thromboembolic risk in ET than in CAD. We aimed to investigate the antiplatelet effect of aspirin and platelet turnover in ET versus CAD patients. Methods We included 48 ET patients and an age-matched group of 48 CAD patients. The effect of aspirin was evaluated by thromboxane B2 (TXB2) levels and platelet aggregation. Platelet turnover was assessed by immature platelet count (IPC) and immature platelet fraction (IPF). Results ET patients had reduced effect of aspirin compared with CAD patients, demonstrated by significantly higher TXB2 levels (median of differences = 22.3 ng/mL, p < 0.0001) and platelet aggregation (median of differences = 131.0 AU*min, p = 0.0003). Furthermore, ET patients had significantly higher IPC (p < 0.0001) and IPF (p = 0.0004) than CAD patients. Conclusion ET patients have lower 24-hour antiplatelet effect of aspirin than CAD patients. This may be explained by an increased platelet production and turnover counteracting the antiplatelet effect of aspirin. These findings strengthen the rationale for exploring novel antiplatelet regimens in ET patients to reduce the risk of cardiovascular events.

Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease

2008 ◽  
Vol 100 (10) ◽  
pp. 626-633 ◽  
Author(s):  
Christoph arenhorst ◽  
Stefan James ◽  
John T. Brandt ◽  
Joseph A. Jakubowski ◽  
Kenneth J. Winters ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Platelet Activation ◽  
Maintenance Dose ◽  
Stable Coronary Artery Disease ◽  
Loading Dose ◽  
Activation Markers ◽  
Fluorescent Intensity ◽  
Artery Disease

SummaryPrasugrel, a novel P2Y12 ADP-receptor antagonist, has been reported to achieve greater inhibition of platelet aggregation compared to clopidogrel as assessed by light transmission aggregometry. It was the objective of this study to investigate the effect of prasugrel on alternative markers of platelet activation in comparison to a high loading dose and the approved maintenance dose of clopidogrel. One hundred ten aspirintreated patients with stable coronary artery disease were randomized to a loading dose (LD, day 1)/ maintenance dose (MD, days 2–29) of prasugrel 60 mg/10 mg or clopidogrel 600 mg/75 mg. Platelet activation markers were analyzed by whole blood flow cytometry pre-dose and at 2 and 24 hours after LD and pre-dose at 14 and 29 days. After stimulation with 20 µM ADP, 2 hours after LD, significantly lower expression of activated GPIIb/IIIa (4.3 vs. 21.8 [mean fluorescent intensity (MFI)], p < 0.001) and P-selectin (2.0 vs. 11.7 MFI, p < 0.001) along with decreased formation of platelet-monocyte aggregates (16.4% vs.29.6% positive cells, p < 0.001) was observed with prasugrel versus clopidogrel. All these effects were maintained through 24 hours and during the MD period. In conclusion, prasugrel 60 mg LD and 10 mg MD inhibit several markers of platelet activation and the formation of platelet-monocyte aggregates more effectively than a 600 mg LD and 75 mg MD of clopidogrel. Attenuated platelet aggregation and reduced expression of platelet procoagulant and pro-inflammatory markers with prasugrel suggest the potential to reduce cardiovascular events both in the acute setting and in longterm treatment.

scholarly journals Relationship Between the Serum sCD40L Level and Aspirin-Resistant Platelet Aggregation in Patients With Stable Coronary Artery Disease

2008 ◽  
Vol 72 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Burak Pamukcu ◽  
Huseyin Oflaz ◽  
Imran Onur ◽  
Kenan Midilli ◽  
Gulden Yilmaz ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Platelet Aggregation ◽  
Stable Coronary Artery Disease ◽  
Artery Disease ◽  
Scd40l Level
Sign in / Sign up

Export Citation Format

Share Document